title: Bezafibrate and clofibric acid are novel inhibitors of phosphatidylcholine synthesis via the methylation of phosphatidylethanolamine.
abstract: The effects of bezafibrate and clofibric acid, fibrate hypolipidemic agents, on phosphatidylcholine (PC) synthesis via the phosphatidylethanolamine (PE) methylation pathway were studied. In cultured rat hepatocytes, bezafibrate and clofibric acid added to the medium rapidly and markedly reduced the conversion of ethanolamine-labeled PE to PC (IC50 30 and 150 microM, respectively). Furthermore, the methylation of PE derived from serine was also blocked by bezafibrate, as was the secretion of PC derived from either serine or ethanolamine. The microsomal activity of PE N-methyltransferase was inhibited by these agents. Perfluorooctanoic acid but not DCQVA, though both are potent peroxisome proliferators comparable to fibrates, produced this inhibition. The inhibitory effects produced by these agents were diminished by dithiothreitol (DTT) added to the assay or alkaline pH assay condition. Inhibition by oleic acid was also attenuated under these conditions, suggesting a common mechanism of inhibition. However, unlike fatty acids, fibrates did not have rapid stimulatory effects on the CDP-choline pathway in hepatocytes. These results suggest that fibrates may mimic fatty acids in regulating PC synthesis from the PE methylation pathway but not the CDP-choline pathway.
authors.affiliation: National Institute of Health Sciences, Tokyo, Japan. mogami@nihs.go.jp
authors.forename: T
authors.initials: T
authors.lastname: Nishimaki-Mogami
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: E
authors.initials: E
authors.lastname: Okochi
authors.forename: A
authors.initials: A
authors.lastname: Takahashi
mesh_terms: D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology; D002087:Butyrates / Q000494:pharmacology*; D002478:Cells, Cultured; D019916:Choline-Phosphate Cytidylyltransferase; D002995:Clofibric Acid / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D008099:Liver / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D008745:Methylation / Q000187:drug effects; D008780:Methyltransferases / Q000037:antagonists & inhibitors*; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology; D009713:Nucleotidyltransferases / Q000187:drug effects; D010713:Phosphatidylcholines / Q000096:biosynthesis*; D050918:Phosphatidylethanolamine N-Methyltransferase; D010714:Phosphatidylethanolamines / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013439:Sulfhydryl Reagents / Q000494:pharmacology
chemical_list: D002087:Butyrates; D004791:Enzyme Inhibitors; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D013439:Sulfhydryl Reagents; D002995:Clofibric Acid; D008780:Methyltransferases; D050918:Phosphatidylethanolamine N-Methyltransferase; D009713:Nucleotidyltransferases; D019916:Choline-Phosphate Cytidylyltransferase; D001629:Bezafibrate